Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Year: 2016
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet
Authors: Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols, Diego L Cortinovis, Joseph Leach, Jonathan Polikoff, Carlos Barrios, Fairooz Kabbinavar, Osvaldo Arén Frontera, Filippo De Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S Chen, Alan Sandler, David R Gandara
Institutions: Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Genentech, Samsung Medical Center, Sungkyunkwan University, University of Campania "Luigi Vanvitelli", Asklepios Fachkliniken München-Gauting, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Aichi Cancer Center, The Maria Sklodowska-Curie National Research Institute of Oncology, Hospital Regional Universitario de Málaga, Azienda Ospedaliera San Gerardo, Minnesota Oncology, Pontifícia Universidade Católica do Rio Grande do Sul, University of California, Los Angeles, European Institute of Oncology, Istanbul University-Cerrahpaşa, Seoul National University, Seoul National University Bundang Hospital, University of California Davis Medical Center, UC Davis Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Gilead Sciences, Ariad Pharmaceuticals, F. Hoffmann-La Roche, Taiho Pharmaceutical, Boehringer Ingelheim Japan, Dainippon Sumitomo Pharma, Eisai, Astellas Pharma, Genentech, Allergan, Chugai Pharmaceutical, National Cancer Institute, Daiichi Sankyo Europe
Award: CANCER CENTER SUPPORT GRANT
OpenAlex ID: W2567564314